DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in AVEED is testosterone undecanoate. There are sixty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the testosterone undecanoate profile page.
Generic Entry Opportunity Date for 022219
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||INJECTABLE;INTRAMUSCULAR||Strength||750MG/3ML (250MG/ML)|
|Approval Date:||Mar 5, 2014||TE:||RLD:||Yes|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Mar 14, 2027||Product Flag?||Y||Substance Flag?||Delist Request?|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Feb 27, 2026||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).|
Complete Access Available with Subscription